

- cn4
C₁
59. The combination of claim 54 wherein the combination retains the ability to initiate a Th1-type response.--
-

In the specification:

Please replace the paragraph beginning on line 6 of page 1 with the following rewritten paragraph:

C₂

-- This is a divisional of Serial No. 09/141,220, filed August 27, 1998, which claims priority to U.S. Serial No. 60/074,590 filed February 13, 1998, entitled "Mutagenized IgE-Binding Epitopes for Ara H 1", by A. Wesley Burks, Jr., Ricki M. Helm, Gael Cockrell, Gary A. Bannon, J. Steven Stanley, and David Shin; U.S. Serial No. 60/074,624 filed February 13, 1998, entitled "Peanut Allergen Ara H 3" by A. Welsey Burks, Jr., Hugh Sampson, Gary A. Bannon, Shau-Ku Huang, and Patrick A. Rabjohn; U.S. Serial No. 60/074,633 filed February 13, 1998, entitled "Mutagenized IgE-Binding Epitopes for Ara H 2" by A. Wesley Burks, Jr., Ricki M. Helm, Gael Cockrell, Gary A. Bannon, J. Steven Stanley, and Nina King; U.S. Serial No. 09/240,557 filed January 29, 1999, which claims priority to U.S.S.N. 60/073,283 filed January 31, 1998; U.S. Serial No. 09/241,101 filed January 29, 1999, which claims priority to U.S.S.N. 60/073,283 filed January 31, 1998; U.S. Serial No. 09/248,673 filed February 11, 1999, which claims priority to U.S.S.N. 60/073,283 filed January 31, 1998; and under 35 U.S.C. §§ 120 and 371 to PCT/US96/15222 entitled "Peanut Allergens and Methods" filed September 23, 1996, by University of Arkansas, and U.S. Serial No. 08/717,933 filed September 23, 1996.--

Please replace the paragraph beginning on line 12 of page 15 with the following rewritten paragraph:

C₃

--Therapy or desensitization with the modified allergens can be used in combination with other therapies, such as allergen-non-specific anti-IgE antibodies to deplete the patient of